Quebec Funding, Drug Trends, and New Weight-Loss Pill Foundayo

In this episode, Dr. Chi-Ming Chow begins by discussing Quebec's funding for English-speaking patients and its potential impact on healthcare access. He then highlights alarming trends in drug use in the United States, focusing on medetomidine and fentanyl, their risks, clinical effects, and challenges in managing these substances. Dr. Chow explores fluvoxamine as a potential treatment for long COVID, examining ongoing research and findings. The episode introduces the new weight-loss pill Foundayo, sharing clinical trial results, applications, benefits, side effects, and safety considerations. The episode concludes with closing remarks and a preview of tomorrow's topics. (0:00) Welcome, episode overview, and Quebec funding for English-speaking patients (1:58) Alarming trends in drug use in the United States (2:40) Medetomidine and fentanyl: risks, clinical effects, and challenges (6:22) Fluvoxamine as a potential treatment for long COVID (9:54) Introduction and clinical trial results of the new weight-loss pill Foundayo (11:16) Applications, benefits, side effects, and safety of Foundayo (13:01) Closing remarks and tomorrow's episode preview